Immunic (IMUX) Akcija Kursas
Immunic Kursas
Analitikų tikslinės kainos mediana yra 20,50 USD, t. y. virš dabartinę kainą 193,3 %. Iš 19 analitikų 18 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Immunic akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Immunic akcija ir akcijų analizė
Dažnai užduodami klausimai apie Immunic akciją
Immunic Inc is primarily present in the United States.
Immunic Inc represents a strong commitment to advancing the treatment of autoimmune diseases and chronic inflammatory conditions. The company's corporate philosophy is centered around pioneering innovative therapies that address unmet medical needs, backed by extensive research and development. Immunic Inc prioritizes patient-centricity, aiming to enhance quality of life through effective and safe treatment options. With a focus on excellence and scientific rigor, Immunic Inc strives to deliver groundbreaking therapies that can make a meaningful difference in patients' lives.
The business model of Immunic Inc. is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases. The company aims to leverage its deep understanding of the immune system and expertise in small molecule drug development to create potential treatments that target specific diseases. Through its research and development efforts, Immunic Inc. seeks to address unmet medical needs and improve the lives of patients suffering from a range of disorders, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. By combining scientific knowledge with a patient-centered approach, the company strives to provide effective and accessible therapies in the field of immunology.
Immunic Inc is primarily active in the pharmaceutical industry.
The main competitors of Immunic Inc in the market are [insert competitor names here].
Immunic Inc. is a pharmaceutical company specializing in the development of innovative therapies for autoimmune diseases and chronic inflammatory disorders. Founded in 2016, Immunic Inc. has quickly emerged as a key player in the field. The company is focused on leveraging its expertise in small molecule drug development to address unmet medical needs. Immunic Inc. is committed to advancing its pipeline of potential treatments, utilizing a targeted approach to modulate the immune system and provide patients with novel therapeutic options. With a strong dedication to research and development, Immunic Inc. aims to make a significant impact on patients' lives and contribute to the advancement of healthcare.
Immunic Inc, a leading biopharmaceutical company, has reached several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its novel therapeutic candidate, IMU-838, in patients with relapsing-remitting multiple sclerosis. The encouraging results demonstrated its potential in reducing disease activity and progression. Additionally, Immunic Inc achieved the initiation of Phase 2 clinical trials for IMU-935, an orally available small molecule targeting chronic inflammatory and autoimmune diseases. These milestones represent the company's commitment to developing innovative therapies addressing unmet medical needs. Immunic Inc continues to advance its pipeline, striving to provide effective treatments for patients globally.
Analitikai šiuo metu nustato vidutinę Immunic akcijos tikslinę kainą 22,13 USD (mediana: 20,50 USD), t. y. +216,6 % palyginti su paskutine kaina. Konsensusas pagrįstas 19 analitikų reitingais.
19 analitikai šiuo metu vertina Immunic akciją: 18 rekomenduoja pirkti, 1 laikyti ir 0 parduoti.
Pagal dabartinį kursą Immunic akcija kainuoja 6,37 EUR (6,99 USD).
Immunic akcija (IMUX) kotiruojama 5 biržose, įskaitant: NASDAQ (IMUX), Frankfurt (10VA.F), München (10VA.MU), Düsseldorf (10VA.DU).
Immunic Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of immune and inflammatory diseases.The company's business model is based on four main pillars: research and development, clinical studies, product distribution, and partnerships.
Pelnas šiuo metu negali būti apskaičiuotas Immunic.
tikėtina grynasis pelnas Immunic yra −408,83 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Immunic šiuo metu yra −0,21. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Immunic akcijos vertę.
KUV šiuo metu negali būti apskaičiuotas Immunic.
Eulerpool kokybės balas Immunic yra 5/10.
Immunic ISIN yra US4525EP1011. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Immunic WKN yra A2PHD4. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Immunic prekybos žymė yra IMUX. Ši biržos žymė naudojama Immunic akcijoms prekiauti biržoje.
Immunic akcija
Immunic Pagrindiniai konkurentai
Immunic Biržos simbolis
Immunic FIGI
Visos Immunic pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Immunic akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Immunic. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: